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Abstract
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are usually asymp-
tomatic for decades, thus targeted screening can prevent liver disease by timely diagnosis
and linkage to care. More robust estimates of chronic HBV and HCV infections in the general
population and risk groups are needed. Using a modified workbook method, the total number
of ever chronically infected individuals in the Netherlands in 2016 was determined using
population size and prevalence estimates from studies in the general and high-risk population.
The estimated 2016 chronic HBV infection prevalence is 0.34% (low 0.22%, high 0.47%), cor-
responding to approximately 49 000 (low 31 000, high 66 000) HBV-infected individuals aged
15 years and older. The estimated ever-chronic HCV infection prevalence is 0.16% (low
0.06%, high 0.27%), corresponding to approximately 23 000 (low 8000, high 38 000) ever-
chronic HCV-infected individuals. The prevalence of chronic HBV and HCV infections in
the Netherlands is low. First-generation migrants account for most infections with 81% and
60% of chronic HBV and HCV infections, respectively. However, about one-fifth of HCV
infections is found in the general population at low risk. This method can serve as an example
for countries in need of more accurate prevalence estimates, to help the design and evaluation
of prevention and control policies.
Introduction
Worldwide, it is estimated that 248 million people are chronically infected with hepatitis B
virus (HBV) [1] and that 71 million are chronically infected with hepatitis C virus (HCV)
[2]. HBV and HCV infection prevalence varies across different regions. In the countries of
the European Union (EU) and European Economic Area (EEA), approximately 4.7 million
people live with chronic HBV and 5.6 million people are anti-HCV positive, which is 0.9%
(95% CI 0.7–1.2) and 1.1% (95% CI 0.9–1.4) of the population, respectively [3]. In 2015, an
estimated 702 000 and 495 000 people worldwide died of chronic hepatitis B or hepatitis C
or related liver diseases, respectively [4]. In Europe (Global Burden of Disease region), this
was 74 500 and 114 600 for HBV and HCV, respectively [4]. Globally, chronic infections
with HBV and HCV are responsible for the majority of cases of liver cirrhosis (57%) and hepa-
tocellular carcinoma (78%) [5]. Because chronic HBV and HCV infections are usually asymp-
tomatic for several decades before irreversible damage is evident, they remain undetected until
treatment options become limited. Approximately 20% of people with untreated chronic HBV
and 15–30% of people with chronic HCV infection are estimated to develop cirrhosis within
20 years [6, 7]. It was estimated that in the Netherlands approximately 500 people died annu-
ally between 2002 and 2015 due to the consequences of chronic HBV or HCV infection [8].
This end-stage disease and mortality is to a large extent avoidable as safe and effective antiviral
treatment became available for chronic active HBV infections and direct-acting antivirals
(DAAs) are accessible for all patients with chronic HCV infection in the Netherlands in recent
years.
To eliminate HBV and HCV as a public health threat the World Health Organization
(WHO) set targets, including 90% diagnosis coverage of all individuals chronically infected
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with HBV and HCV by 2030 [9]. In 2016 the Health Council of
the Netherlands advised targeted screening within high-risk
populations [10]. Previous studies estimated the prevalence of
chronic HBV infection, anti-HCV antibodies and chronic HCV
infection in the Netherlands. A national serosurvey in 2006–
2007 in the Netherlands estimated a weighted seroprevalence of
0.2% for HBsAg and of 0.3% for anti-HCV antibodies in the gen-
eral Dutch population [11, 12]. However, because HBV and HCV
infections are concentrated within high-risk groups such as
migrants, men who have sex with men (MSM) and people who
inject drugs (PWID) – which are often underrepresented in (vol-
untary) national serosurveys [13] – these estimations are possibly
an underestimation. In the past 5 years, multiple prevalence esti-
mates from studies among migrants in the Netherlands became
available [14–19]. To design appropriately targeted screening
interventions, robust prevalence estimates are needed for the gen-
eral population and different risk groups. The European Centre
for Disease Prevention and Control has called for more accurate
prevalence estimates in EU/EEA countries to better inform pre-
vention and control policies [20]. Therefore, we aim to determine
the overall and risk group-specific prevalences of chronic HBV
(HBsAg-positive) and HCV (ever HCV-RNA positive) in the
Netherlands in 2016.
Methods
Workbook method
The prevalence of chronic HBV and HCV infection in the
Netherlands in 2016 was estimated by using the workbook
method. The workbook method has been developed by the
Joint United Nations program on HIV/AIDS (UNAIDS) and
the WHO, in collaboration with the UNAIDS Reference Group
on Estimates, Modeling and Projections for estimating the HIV/
AIDS prevalence in low endemic countries with concentrated epi-
demics [21]. The following risk groups and a group at low risk
were distinguished:
(1) First-generation migrants originating from low-intermediate
to high prevalence countries, subdivided by country-of-origin
(2) HIV-positive MSM
(3) HIV-positive PWID
(4) HIV-positive non-MSM non-PWID (HCV only)
(5) HIV-negative MSM (HBV only)
(6) HIV-negative PWID
(7) Haemophilia patients treated before 1992 (HCV only)
(8) Female sex workers (HBV only)
(9) Individuals at low risk for infection
For HBV and HCV separately, low and high estimates of the
population size and the prevalence of chronic infection within
these subsets were derived from (un)published studies, national
registries and personal communication with experts. MEDLINE
and EMBASE databases were searched for HBV and HCV infec-
tion prevalence studies in the Netherlands that included preva-
lence estimates for the described risk groups and/or the general
population. Bibliographies of identified studies were also searched
for relevant articles. In addition, information was requested from
Dutch experts working in the field of hepatitis research to obtain
the most recent data from unpublished studies. A list of all
selected studies was sent for review to an expert panel (consisting
of medical doctors, epidemiologists, a public health nurse and a
policy advisor) to ensure completeness. Chronic HBV infection
refers to hepatitis B surface antigen (HBsAg) positivity. Chronic
HCV infection refers to viraemic infection, i.e. HCV-RNA posi-
tivity. When studies only reported the anti-HCV antibody preva-
lence, this was adjusted with a correction factor of 0.74 to account
for spontaneous viral clearance [22]. We estimate the number of
ever-chronically-infected individuals, including those who were
successfully treated. As prevalence estimates mostly refer to
adult populations, we used population size estimates for the popu-
lation aged 15 years and older. High and low population size esti-
mates were multiplied by high and low estimates of HBsAg and
HCV-RNA prevalences to produce estimates of the average num-
ber of individuals ever chronically infected with HBV and HCV,
respectively.
Risk group population size and prevalence
First-generation migrants originating from low-intermediate to
high endemic countries
First-generation migrants were defined as individuals born outside
of the Netherlands with at least one parent also born abroad.
Second-generation migrants were not defined as risk population,
because it was described that chronic viral hepatitis prevalences
among them were similar to the general population [11, 12]. The
numbers of first-generation migrants aged 15 years and older in
2016, stratified by country-of-origin, were obtained from Statistics
Netherlands [23]. The population sizes determined by Statistics
Netherlands are the most accurate estimates available; we therefore
did not use a different low and high estimate of the population size
per migrant group but used the Statistics Netherlands estimate for
both the low and high population size estimate. All migrant groups
were listed as separate risk groups by country-of-origin in thework-
books for HBV and HCV if they included at least 500 individuals
and if the HBsAg and HCV-RNA prevalence estimates for these
groups were at least 1.0% and 0.5% in the country-of-origin,
respectively. We chose relatively low cut-off points to increase the
precision of the prevalence estimations. We lowered the cut-off
value for HCV to 0.5% because otherwise people born in
Morocco, Turkey and Surinam (the three largest migrant popula-
tions in the Netherlands) would not be included in the analysis.
Using these cut-offs, we included 79 migrant groups for HBV and
96 migrant groups for HCV. Migrant groups including less than
500 individuals (in total 22 388 migrants from 118 different
countries, comprising 1.2% of all first-generation migrants) and
migrants from low prevalence countries (29% and 15% of all first-
generationmigrants forHBVandHCV, respectively) were included
in the group of individuals at low risk of infection.
For HBsAg and HCV-RNA prevalences among first-
generation migrants in the Netherlands, we distinguished (1)
population-based prevalence studies (i.e. participants were ran-
domly selected from a population register) conducted in the
Netherlands, which included migrants from various endemic
countries and (2) screening studies performed in the
Netherlands that offered screening for HBV and/or HCV to
migrants from selected countries. Only screening studies includ-
ing 100 or more participants were considered. If both population-
based and screening studies were available for a specific country,
only the results from the population-based studies were used,
because these are less likely to be biased than screening studies,
in which people could have participated selectively.
If no population-based or screening studies from the
Netherlands were available, prevalence estimates for the
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country-of-origin were used as a proxy for the prevalence among
migrants from that country. These estimates were derived from
Schweitzer et al. [1] and the Polaris Observatory [2] for HBV
and HCV, respectively. If also no country-specific estimates were
available, regional HBV and HCV estimates (derived from
Kowdley et al. [24] for HBV and the Polaris Observatory [2] for
HCV) were used. It has previously been described that HBV preva-
lence estimates for the country-of-origin are often higher than the
prevalence among migrants from that country, while for HCV they
seem more comparable [20]. However, a Dutch study examining
the HCV prevalence among migrants in the Netherlands suggested
that the prevalence among migrants was lower compared with the
prevalence in the country of origin [25]. To investigate whether a
correction factor would be appropriate for the country-of-origin
HBV and/or HCV prevalence estimates, we compared estimates
derived from studies in the Netherlands with country-of-origin
estimates for 10 countries for HBV and nine for HCV for which
both were available. The statistical methods and results of this com-
parison are described in the supplementary material. For the
majority of countries for which data were available the prevalence
was slightly higher in the country of origin but no statistically sig-
nificant differences were observed. We therefore did not use a
correction factor for country-of-origin prevalence estimates.
Supplementary Tables S3 (HBV) and S4 (HCV) specify which
prevalence estimate sources were used for every specific country.
In total, for HBV, a local estimate was available for 10 countries
of origin (covering 64% of the foreign-born population) and coun-
try/region-of-origin estimate for 69. For HCV, a local estimate was
available for eight (covering 42% of the foreign-born population) of
96 countries.
HIV-positive individuals
The Dutch Stichting HIV Monitoring (SHM, HIV Monitoring
Foundation) collects longitudinal data of all newly registered
HIV-infected individuals in the Netherlands and provides esti-
mates of the size of the undiagnosed population [26]. The SHM
maintains an up-to-date patient database including HBV and
HCV status and risk group. We included HIV-positive MSM
and HIV-positive PWID (both diagnosed and undiagnosed as
estimated by the SHM) as separate risk groups. Because the
majority (84%) of the non-MSM non-PWID HIV-positive indivi-
duals co-infected with HBV are of non-Western European des-
cent (SHM, personal communication, April 2017), they were
not defined as a separate risk group in the HBV workbook in
order to prevent overlap with the first-generation migrant groups.
On the contrary, since non-MSM non-PWID HIV-positive indi-
viduals co-infected with HCV are mostly (56%) of Dutch or
Western European descent (SHM, personal communication,
April 2017), this group was included as a separate risk group in
the HCV workbook. The population size estimates derived from
SHM were used as both low and high estimates in the workbooks.
The SHM provided the prevalence of ever being diagnosed with a
chronic HBV or HCV infection, stratified by transmission group.
HIV-negative MSM and PWID
The estimated number (low and high estimate identical) of
HIV-negative MSM was derived from the estimated MSM popu-
lation size in the Netherlands by Op de Coul et al. [27] minus the
estimated number of HIV-positive MSM by SHM [26]. The HBV
prevalence estimate for MSM was derived from the hepatitis B
vaccination program for risk groups [28]. The estimated numbers
(low and high estimates) of HIV-negative PWID were derived
from estimates on the total PWID population size in the
Netherlands by the Dutch Focal Point for the European
Monitoring Center for Drugs and Drug Addiction [29] and the
Netherlands Institute for Mental Health and Addiction [30]
minus the estimated number of HIV-positive PWIDs by SHM
[26]. It is important to note that PWID in the Netherlands is
mostly ever-injectors rather than current-injectors and that num-
bers used concern opiate injectors. It is expected that the group of
amphetamine and/or cocaine injectors is relatively small and do
not contribute to transmission. Data from addiction care services
indicate that the whole country counts less than 1000 injectors, of
whom the far majority is a heroin injector. The main route of
administration in crack cocaine users is basing and in amphet-
amine users swallowing. This information is based on expert opi-
nions and fieldwork. HBV and HCV prevalence estimates among
PWID were derived from a study among people who use drugs in
The Hague, performed by the National Institute of Public Health
and the Environment [31] and from the Amsterdam Cohort
Studies among people who use drugs [32].
Haemophilia patients treated before 1992 (HCV only)
HCV is an important co-morbidity among haemophilia patients
who received blood products (clotting factor concentrates) before
1992. Donor screenings for HCV were not introduced in the
Netherlands until 1992 and 98% of patients ever treated before
1992 with large pool (i.e. derived from more than 1000 different
donors) non-HCV-safe clotting factor concentrate was infected
with HCV [33]. Low and high estimates for the number of
haemophilia patients treated before 1992 who currently live in
the Netherlands were derived from the Van Creveld Clinic, the
largest haemophilia treatment centre in the Netherlands (Dr
E. P. Mauser-Bunschoten, personal communication, April 2017)
and Vriend et al. [34], respectively. Prevalence estimates were
derived from a cross-sectional study among haemophilia patients
in 2005 [35].
Female sex workers (HBV only)
Female sex workers were defined as sex workers working in broth-
els and clubs, working as escorts, or working on the street. In 1998,
The European Network for HIV/STD Prevention in Prostitution
(Europap) estimated that between 20 000 and 25 000 sex workers
were active in the Netherlands [36]. Although dated, this is cur-
rently the best estimate. An estimated 12% of sex workers are
male or transgender [37] and were deducted from the population
size. HBV prevalence estimates for female sex workers were
derived from surveillance data regarding HBV vaccination [38],
STI clinic visitors [39] and outreach activities [39].
Individuals at low risk of infection
Individuals not classified as one of the aforementioned risk
groups were defined as the population at low risk of infection.
The low and high population size estimates were calculated by
subtracting the low and high population size estimates of the
risk groups from the total number of individuals aged 15 and
older in the Netherlands, obtained from Statistics Netherlands
[23]. In 2016, the total population in the Netherlands was almost
17 million, of which 14.2 million were aged 15 years and older.
Prevalence estimates were derived from the screening of first
time blood donors [40], an HCV prevalence-study among a ran-
dom sample of pregnant women in Amsterdam [25], a
population-based prevalence study among Amsterdam residents
[41], a community-based screening project in the Rotterdam
Epidemiology and Infection 3
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region [42] and from the national serosurvey PIENTER-2 [11,
12]. Because several studies reported an HCV-RNA prevalence
of 0% among individuals at low risk of infection, this was used
as the low HCV-RNA estimate.
Statistical analysis
The prevalence estimates for each population group based on the
identified studies were calculated using the workbook calculations
and the upper and lower limits of the 95% confidence intervals
were chosen as the high and low estimates, respectively. To obtain
estimates the following procedure was applied: If multiple studies
with numerator and denominator data were available, the results
were pooled using meta-analyses, using the meta package in the R
statistical computing environment [43]. Heterogeneity (I2) was
calculated and random effects were taken into account if hetero-
geneity was significant; otherwise, a fixed model was chosen.
Because several studies included zero-event data, a continuity cor-
rection was applied to all analyses to include these studies.
Freeman-Tukey double arcsine transformations were used to cal-
culate the overall prevalence and 95% confidence interval. If only
one study was available reporting HBV or HCV prevalence
(including numerator and denominator data), a 95% confidence
interval was calculated using the Clopper-Pearson method with
the binom package in R. If two or more studies were available
that reported data without numerator and denominator data
(e.g. only ranges) of that risk group, the highest and lowest
reported estimates were used as high and low estimate in the
workbook.
Results
Chronic HBV infections in the Netherlands
Table 1 summarizes the estimated population size and chronic
HBV prevalence per population group. The overall prevalence
of chronic HBV infection among individuals aged 15 and older
in the Netherlands was estimated at 0.34% (low 0.22%, high
0.47%), which corresponds to 48 756 (low 31 237, high 66 461)
HBV infected individuals. First-generation migrants accounted
for most HBV infections (81%), with an estimated 39 521 (min
27 969, max 51 073) infected individuals. The migrant groups
that were estimated to harbour most chronic HBV infections in
the Netherlands are migrants from Turkey, Somalia and China
with 18.9%, 8.3% and 6.5% of HBV infections among migrants,
respectively (Fig. 1). Supplementary Table S3 shows the estimated
population size, HBV prevalence and number of infected indivi-
duals per country-of-origin. HIV-negative MSM accounted for
the second largest number of infections (1237; low 788, high
1744).
Chronic HCV infections in the Netherlands
Table 2 summarizes the estimated population size and chronic
HCV prevalence per population group. The overall prevalence
of ever having been chronically infected with HCV among indivi-
duals aged 15 and older in the Netherlands was estimated at
0.16% (low 0.06%, high 0.27%). This corresponds to 22 885
(low 8461, high 37 809) individuals. Concordant with HBV, first-
generation migrants comprise the largest group of HCV infected
individuals (60%), with 13 819 (low 5671, high 21 967) ever
chronically infected individuals. The migrant groups that were
estimated to harbour most chronic HCV infections in the
Netherlands are migrants from Surinam, Morocco and the former
Soviet Union with 21.2%, 10.1% and 8.2% of HBV infections
among migrants, respectively (Fig. 1). Supplementary Table S4
shows the estimated population size and HCV prevalence per
country-of-origin. HIV-negative PWID are the second largest
group with an estimated 3131 (min 1522, max 5189) ever chron-
ically infected individuals. Figure 1 shows the first-generation
migrant groups with the highest absolute number of chronic
HBV and HCV infected individuals for the countries of origin
with the largest number of (combined) infections.
Discussion
The chronic HBV prevalence of 0.34% in the Netherlands is
among the lowest prevalences in Europe [1] and the chronic
HCV prevalence of 0.16% is among the lowest in the world [2].
Detailed insight in the prevalence and estimated number of peo-
ple with chronic infection in specific risk group is given, for first-
generation migrants by country of birth. First-generation
migrants account for most infections with 81% of HBV and
60% of HCV infections.
Recently, WHO published their global strategy on viral hepa-
titis 2016–2021 [9], in which they give directions to getting to
know the epidemic in the country in order to tailor health invest-
ments well. Furthermore, in the 2017 Global Hepatitis Report
they reported that, while global estimates are taking shape, key
data remains missing in many countries [44]. Our method
could serve as an example of an accessible method to estimate
risk group specific and overall HBV/HCV prevalences.
Our study is, however, subject to several limitations. Firstly, it
should be noted that several relatively small risk groups (e.g.
haemodialysis patients, HIV-negative MSM using pre-exposure
prophylaxis (PrEP) [45] and asylum seekers or undocumented
migrants) were not specifically included in our calculations.
Due to their limited size (e.g. due to the severely lower life expect-
ancy a limited number of haemodialysis patients treated before
1992 is expected to be currently alive, only 376 MSM were partici-
pating in a PrEP demonstration project in the Netherlands is 2016
[45]), we do not expect this to majorly influence the overall preva-
lence. First-generation migrant children under the age of 15 were
also not included. We decided not to include this group because
the prevalence data available from Dutch studies among migrants
did not include children. As the prevalence among children is
expected to be lower, applying adult prevalence estimates to the
total population including children would have resulted in an
overestimation of the population with chronic viral hepatitis.
Secondly, although we attempted to use the best available data,
some data were subject to different types of bias that possibly
influenced the outcomes. Prevalence estimates for haemophilia
patients and female sex workers were derived from studies con-
ducted 10–15 years ago and may no longer be accurate.
However, they are, to date, the best source available. In addition,
we combine data sources that use different methodologies to esti-
mate population sizes (i.e. for HIV-negative MSM). These num-
bers may not be fully compatible and should be viewed with
some caution. Prevalence estimates derived from studies among
first-generation migrants in the Netherlands were available for
64% and 42% of the migrant population for HBV and HCV,
respectively. For the remaining migrants, prevalence estimates
were derived from studies in the countries of origin. As we
showed in the supplementary material, for some countries these
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country-of-origin data may overestimate the prevalence among
migrants. This may be explained by a lower risk of exposure
after migration to a lower prevalence country and epidemiological
phenomena such as the healthy migrant effect or salmon bias
[46]. Furthermore, HBV prevalences for nine countries and
HCV prevalences for six countries were derived from targeted
screening studies rather than population-based studies. In a sep-
arate analysis (data not shown), we tested for differences between
prevalence estimates from screening and population-based studies
among Turkish migrants for which three studies of both types
were available. We found a significant lower HBV prevalence in
screening studies among Turkish migrants than in population-
based studies (2.54% vs. 4.11%, p < 0.05). This suggests, for
HBV among Turkish migrants at least, that prevalence estimates
from screening studies may underestimate the prevalence in the
population. A further limitation is that we estimated the total
number of people who ever had, or currently have, a chronic
HCV infection. The prevalence of current chronic HCV infection
will be slightly lower as individuals successfully treated (estimated
at 4427 from 2009 to 2015, of which 2000 successfully treated
with DAAs in 2015) have lost their HCV RNA [47].
Unfortunately, data on diagnoses and treatment outcomes are
not available at the risk group level in the Netherlands, except
for HIV-infected individuals.
Our chronic HBV prevalence estimate is lower than a previous
study by Marschall et al. in 2006 [48], that used country-of-birth
prevalence data for the migrant groups, which might be an over-
estimation, at least for some countries, as we showed in our ana-
lyses. Another explanation for the lower prevalence we found
might be the reported global decrease in the number of persons
with chronic HBV infection in the past decades [1]. Our chronic
HCV prevalence estimate is concordant with a previous work-
book estimate by Vriend et al. [34]. However, a recent modelling
study by Razavi et al. [49] estimated the chronic HCV prevalence
Table 1. Risk group specific HBsAg prevalence, population size and estimated number of chronic HBV infections
Risk group
HBsAg prevalence Population in the Netherlands Estimated number of chronic HBV cases
% (low–high estimate) (low–high estimate) (low–high estimate)
First-generation migrants from
HBV endemic countriesa
3.08 (2.18%–3.98%) 1 284 654 (1 284 654–1 284 654) 39 521 (27 969–51 073)
HIV+ MSM 3.47 (3.13%–3.81%) 13 650 (13 200–14 100) 474 (413–537)
HIV+ PWID 4.21 (1.95%–6.46%) 511 (310–712) 21 (6–46)
HIV− MSM 0.65 (0.60%–0.70%) 190 265 (131 321–249 209) 1237 (788–1744)
HIV− PWID 3.50 (1.00%–6.00%) 5276 (4357–6194) 185 (44–372)
Female sex workers 1.14 (0.72%–1.56%) 19 800 (17 600–22 000) 226 (127–343)
Individuals at low risk of infection 0.06 (0.02%–0.10%) 12 665 193 (12 602 479–12 727 906) 7093 (1890–12 346)
Total 0.34 (0.22%–0.47%) 14 179 348b 48 756 (31 237–66 461)
HBsAg, Hepatitis B surface antigen; HBV, Hepatitis B virus; MSM, Men who have sex with men; PWID, People who inject drugs.
aFirst-generation migrants from countries with HBsAg prevalence >1.0% of which more than 500 migrants live in the Netherlands.
bTotal population of the Netherlands older than 15 in 2016.
Fig. 1. The number of chronic HBV (yellow) and
ever-chronic HCV (red) infected first-generation
migrants in the Netherlands shown for the top 15
migrant groups with the highest number of HBV
and HCV infections combined (left y-axis).
Triangles (green) indicate the total number of first-
generation migrants living in the Netherlands for
each country (right y-axis).
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in the Netherlands in 2015 at 0.11% (95% uncertainty interval
0.03–0.15), which is slightly lower than our estimate but within
our range of 0.06–0.27. This may be explained by the fact that
they included persons aged <15 years who are at lower risk of
infection and took treatment into account, both lowering the
overall prevalence. Their model, however, does not discriminate
between the different risk groups, leaving the question of how
the infections are distributed in the population unanswered.
The finding that migrants account for most HBV and HCV
infections is concordant with findings from two earlier studies
performed in the Netherlands [34, 48]. The disproportional bur-
den of chronic viral hepatitis among migrants stresses the import-
ance of developing and implementing targeted screening
interventions directed at first-generation migrant populations
for whom – unlike for other risk groups in the Netherlands –
no structural screening programs are in place (besides antenatal
HBV screening of pregnant women). Because the heterogeneity
of the migrant population is high in terms of ethnic origin, risk
for infection and awareness of infection, different screening
approaches may be needed. Good practice examples have been
described, including a toolkit developed by the ‘HEPscreen’ pro-
ject (http://hepscreen.eu/). Our study shows that combining
population size and prevalence estimates per migrant group
gives insight in which migrant groups the highest number of
chronic infections are expected and shows the large differences
between countries of origin and between HBV and HCV. For
example, the largest first-generation migrant population from
hepatitis B or C endemic countries in the Netherlands is origin-
ating from Turkey (Fig. 1). While the intermediate HBV preva-
lence of 4% translates to a high number of chronic HBV
infections, the expected number of HCV infections among
Turkish migrants is very low. In contrast, migrants from the for-
mer Soviet Union are a smaller population but the relatively high
HBV and HCV prevalence indicate that combined screening for
both infections would be justified. An economic evaluation is
needed to gain insight in the conditions when combined HBV/
HCV screening would be cost-effective compared with screening
for HBV or HCV alone, or no screening. Some screening inter-
ventions in the Netherlands have targeted different migrant
groups [14, 16, 18, 19, 42]. These interventions, however, were
once-off, limited in geographical coverage and uptake was often
low/moderate depending on the screening model. A systematic
review of the outcomes of hepatitis C screening programs world-
wide concluded that HCV screening programs in the past identi-
fied only a small portion of the estimated number of
HCV-infected individuals [50]. Systematic screening programs
for migrants are needed to substantially reduce chronic viral
hepatitis-related morbidity and mortality among migrants and
the sustainability, linkage to care and access to treatment has to
be ensured.
Besides the evidently beneficial screening of risk groups, it will
be an even bigger challenge to identify the individuals in the
‘low-risk’ group. These individuals are hidden in the general
population but do account for 15% and 18% of HBV and HCV
infections, respectively. A birth-cohort screening approach,
which was piloted in the south of the Netherlands, was unsuccess-
ful in identifying undiagnosed infections [51]. Vigilance of health
care providers, for example to prompt viral hepatitis testing when
people present with abnormal liver function, is needed to identify
those infected who do not belong to one of the risk groups.
In conclusion, the prevalence of both chronic HBV and HCV
infection in the Netherlands is low and migrants account for most
infections. The risk group-specific prevalence estimates, for first-
generation migrants stratified by country of birth, provide insight
into the distribution of chronic infections. Outcomes can be used
to implement screening effectively and monitor progress towards
the elimination of chronic viral hepatitis.
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Table 2. Risk group specific HCV-RNA prevalence, population size and estimated number of chronic HCV infections
Risk group
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HIV+ MSM 4.92 (4.55%–5.29%) 13 650 (13 200–14 100) 672 (601–746)
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